Antimalarial artesunate–mefloquine versus praziquantel in African children with schistosomiasis: an open-label, randomized controlled trialEmmanuel Bottieau, Katja Polman, Christophe Burm et al.|Nature Medicine|2024Cited by 16
Persistent morbidity in Clade IIb mpox patients: interim results of a long-term follow-up study, Belgium, June to November 2022Nicole Berens‐Riha, Stefanie Bracke, Christophe Burm et al.|Eurosurveillance|2023Cited by 11
Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children (SchistoSAM): protocol of a proof-of-concept, open-label, two-arm, individually-randomised controlled trialClémentine Roucher, Emmanuel Bottieau, Isabel Brosius et al.|BMJ Open|2021Cited by 7